Genflow reports sustained safety and efficacy three months after gene therapy dosing in dog trial

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the European biotechnology company focused on gene therapies for age-related diseases, has reported that positive safety and efficacy signals from its SLAB trial have been maintained three months after the initial dosing period, with no adverse events observed. The SLAB (Sarcopenia and Longevity in Aged Beagles) trial is evaluating Genflow's proprietary SIRT6 centenarian gene therapy in aged dogs, targeting sarcopenia, the age-related loss of muscle mass and strength that also affects humans.